MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
OTCMQB
0.790
-0.030
-3.66%
Opening 10:03 08/10 EDT
OPEN
0.750
PREV CLOSE
0.820
HIGH
0.790
LOW
0.750
VOLUME
4.24K
TURNOVER
3.25K
52 WEEK HIGH
6.30
52 WEEK LOW
0.465
MARKET CAP
8.72M
P/E (TTM)
-0.8394
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (0803-0807)?
Weekly Report · 4h ago
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
Benzinga · 5d ago
Weekly Report: what happened at BCLI last week (0727-0731)?
Weekly Report · 08/03 09:32
BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial
TipRanks · 07/30 21:27
Press Release: BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Dow Jones · 07/28 12:00
*BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman >BCLI
Dow Jones · 07/28 12:00
Weekly Report: what happened at BCLI last week (0720-0724)?
Weekly Report · 07/27 09:34
Weekly Report: what happened at BCLI last week (0713-0717)?
Weekly Report · 07/20 09:32
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including OTCMQB: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.